logo
  

Owens Corning Receives U.S. Antitrust Approval For Masonite Acquisition

Owens Corning (OC) announced Monday the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the company's previously announced acquisition of Masonite International Corp. (DOOR). The expiration of the waiting period occurred at 11:59 p.m. on April 26, 2024.

The expiration of the HSR Act waiting period satisfies a closing condition for the transaction. Masonite previously announced that its shareholders voted to approve the company's acquisition by Owens Corning at its Special Meeting of Shareholders.

The transaction is anticipated to close in May 2024, subject to satisfaction of the remaining customary closing conditions.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Home improvement major Lowe's Companies, Inc. on Tuesday maintained its fiscal 2024 earnings and sales outlook after reporting weak results in its first quarter. However, the quarterly earnings per share were above market estimates. In pre-market activity on the NYSE, Lowe's shares were gaining around 3.1 percent... Veolia (VE) announced Tuesday that its consulting engineering and strategic and operational assistance division Seureca announced the acquisition of MRC Consultants and Transaction Advisers. The financial aspects of the deal are not revealed. The combination of MRC, an energy consulting firm in Spain... French drug major Sanofi is teaming with artificial intelligence or AI startup OpenAI, the developer of highly popular generative AI chatbot ChatGPT, as well as Formation Bio, an AI and tech-driven drug developer, to build AI-powered software to accelerate drug development and bring new medicines more efficiently.

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
Follow RTT